• TwoColModules_AR18CEO.png

    CEO's Strategic report

    As the use of minimally invasive therapies continues to grow, we have the financial resources and capabilities to continue to make targeted new investments, so that we can continue building our Interventional Medicine business and developing leadership positions in attractive growth markets.

    Read more
  • TwoColModules_AR18Chairman.png

    Chairman’s introduction

    With our financial resources and capabilities, I am confident our strategy will create long-term value for all our stakeholders.

    Read more
  • 18 Jun 2018

    Our business model

    By using our strong cash flows to reinvest in product innovation, commercial expansion, clinical studies and complementary acquisitions, we are confident of delivering long-term growth

    See more
  • 18 Jun 2018

    Notice of BTG’s Annual General Meeting

    Our AGM will be held on Wednesday, 18 July 2018 at 10.30 am at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH

    AGM Notice
  • Our objectives

    We monitor our performance against four strategic priorities: delivering products that meet the needs of our customers and their patients; investing for growth; ensuring our people have the right capabilities and our practices are fit for purpose and scalable; and financial key performance indicators.

    Learn more